Liraglutide Treatment in Obese Infertile PCOS Women

Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves s

Trial Details

NCT ID

NCT06742710

Phase

PHASE4

Sponsor

Peking University Third Hospital

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Liraglutide and metformin
Metformin

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723
Beijing, China|39.9075,116.39723
Beijing, China|39.9075,116.39723

Key Eligibility Criteria

Women with polycystic ovary syndrome (PCOS) who meet the Rotterdam diagnostic criteria.
Aged 20-40 years;
25 kg/m2 ≤ BMI ≤ 35 kg/m2;
Have not used any anti-diabetes or weight-loss medications (metformin excluded) within the past 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →